Fig. 5From: Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trialGlycosylated haemoglobin, HbA1c < 7% at 24-week in FDC of MSP vs. MS groupBack to article page